Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REC-3964 in recurrent Clostridioides difficile infection
NCT06536465Phase 2Terminated
- Sponsor
- Recursion Pharmaceuticals
- Start
- Oct 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of REC-163964 in recurrent Clostridioides difficile infection (rCDI) (3 arms), sponsored by Recursion Pharmaceuticals. Primary endpoints: Survival Without Recurrence or Requirement for Additional Clostridioides Difficile Infection Treatment at 8 weeks, Treatment-emergent Adverse Events at 8 weeks and 3 more. Started Oct 2024; status: terminated.
02
Drugs
REC-163964
03
Conditions
recurrent Clostridioides difficile infection (rCDI)
Beyond the preview
Go deeper on NCT06536465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06536465.